The new therapy is known as oncolytic virus therapy, that uses a virus to destroy cancer cells but leaves healthy cells untouched. The FDA has approved one of these therapies to date, called T-VEC ...

As our knowledge of science and the human body expands, so too do doctors have more tools at hand when treating cancer. One relatively recent development in this sphere is the use of oncolytic virus ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.

Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into ...

Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific ...

New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...

Intravenous; NDV: Newcastle disease virus; OS: Overall survival ... Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems.

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

A phase II trial reports success with an innovative immunotherapy for difficult-to-resect basal cell carcinoma, reducing ...